{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:08:26Z","timestamp":1792516106440,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,8]],"date-time":"2013-11-08T00:00:00Z","timestamp":1383868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.expneurol.2013.10.014","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T10:04:04Z","timestamp":1383127444000},"page":"376-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism"],"prefix":"10.1016","volume":"250","author":[{"given":"Patricia K.","family":"Sonsalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christal","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai-Yoong","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharathi S.","family":"Gadad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight C.","family":"German","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2013.10.014_bb0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0006-8993(96)00135-7","article-title":"Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP","volume":"718","author":"Albers","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.it.2009.09.003","article-title":"T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?","volume":"31","author":"Appel","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0015","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/j.1471-4159.1980.tb11206.x","article-title":"Chronic hypoxia in rats: alterations of striato-nigral angiotensin converting enzyme, GABA, and glutamic acid decarboxylase","volume":"34","author":"Arregui","year":"1980","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0020","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10571-009-9368-4","article-title":"Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery","volume":"29","author":"Benicky","year":"2009","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.112.006809","article-title":"A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme","volume":"65","author":"Bernstein","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1096\/fj.05-4553com","article-title":"Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin","volume":"20","author":"Block","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0035","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1471-4159.2009.06425.x","article-title":"Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease","volume":"111","author":"Carta","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0040","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1523\/JNEUROSCI.3061-12.2013","article-title":"Membrane trafficking of NADPH oxidase p47(phox) in paraventricular hypothalamic neurons parallels local free radical production in angiotensin II slow-pressor hypertension","volume":"33","author":"Coleman","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0045","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1046\/j.1471-4159.2000.0742213.x","article-title":"Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo","volume":"74","author":"Dehmer","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0050","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.freeradbiomed.2011.06.033","article-title":"Cross talk between mitochondria and NADPH oxidases","volume":"51","author":"Dikalov","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00165730","article-title":"DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum","volume":"345","author":"Dwoskin","year":"1992","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0065","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.mce.2008.11.003","article-title":"NADPH oxidases and angiotensin II receptor signaling","volume":"302","author":"Garrido","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0070","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00429-012-0402-9","article-title":"Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human susbstantia nigra: an intracellular renin-angiotensin system in the nigra","volume":"218","author":"Garrido","year":"2013","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1742-2094-9-38","article-title":"Involvement of PPAR- in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease","volume":"9","author":"Garrido-Gil","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0080","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cne.903310302","article-title":"Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat","volume":"331","author":"German","year":"1993","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/neur.1996.0041","article-title":"The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse","volume":"5","author":"German","year":"1996","journal-title":"Neurodegeneration"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0075","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2174\/1874467211205030003","article-title":"Parkinson's disease: A role for the immune system","volume":"5","author":"German","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0090","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0022-3565(25)24767-X","article-title":"Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice","volume":"257","author":"Giovanni","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0095","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0022-3565(25)22503-4","article-title":"Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: systemic administration","volume":"270","author":"Giovanni","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0100","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1326-2-1","article-title":"Angiotensin type I receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra","volume":"2","author":"Grammatopoulos","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/157015912804499483","article-title":"NADPH Oxidase and Neurodegeneration","volume":"10","author":"Hernandes","year":"2012","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0110","series-title":"Goodman & Gillman's The Pharmacological Basis of Therapeutics, 12e","article-title":"Renin and Angiotensin","author":"Hilal-Dandan","year":"2011"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0115","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson's disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4899-1376-0_10","article-title":"Interactions of angiotensin II with central dopamine","volume":"396","author":"Jenkins","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0125","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1471-4159.1999.0730214.x","article-title":"Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse","volume":"73","author":"Jenkins","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0130","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1471-4159.2009.05999.x","article-title":"The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease","volume":"109","author":"Joglar","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0135","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1523\/JNEUROSCI.0711-11.2011","article-title":"The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons","volume":"31","author":"Kim-Han","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0009-8981(94)90259-3","article-title":"Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease","volume":"231","author":"Konings","year":"1994","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0145","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1179\/016164104225015949","article-title":"Neuroprotective effect of the angiotensin-converting enzyme inhibitor perindopril in MPTP-treated mice","volume":"26","author":"Kurosaki","year":"2004","journal-title":"Neurol. Res."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0150","first-page":"226","article-title":"Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease","volume":"1","author":"Labandeira-Garcia","year":"2012","journal-title":"Am. J. Neurodegener. Dis."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/neur.1996.0042","article-title":"Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration","volume":"5","author":"Liang","year":"1996","journal-title":"Neurodegeneration"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-510X(02)00081-3","article-title":"Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson's disease","volume":"199","author":"Lin","year":"2002","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0165","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jns.2006.10.018","article-title":"Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease","volume":"252","author":"Lin","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0170","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jnr.20598","article-title":"Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism","volume":"81","author":"Lopez-Real","year":"2005","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0175","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.tips.2008.05.003","article-title":"Role of the renin-angiotensin system in vascular inflammation","volume":"29","author":"Marchesi","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0180","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1357-2725(02)00306-0","article-title":"The brain renin-angiotensin system: location and physiological roles","volume":"35","author":"McKinley","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0185","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00401-008-0350-x","article-title":"Animal models of Parkinson's disease progression","volume":"115","author":"Meredith","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0190","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.neuroscience.2009.04.036","article-title":"Effect of nigrostriatal damage induced by 6-hydroxydopamine on the expression of glial cell line-derived neurotrophic factor in the striatum of the rat","volume":"162","author":"Mertens","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0195","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1073\/pnas.87.15.5720","article-title":"Astrocyte cultures derived from human brain tissue express angiotensinogen mRNA","volume":"87","author":"Milsted","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2006.03.004","article-title":"Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism","volume":"51","author":"Munoz","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0205","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1126\/science.1209200","article-title":"Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation","volume":"334","author":"Nomura","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0210","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neuroscience.2004.04.050","article-title":"Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease","volume":"127","author":"Ochi","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0215","series-title":"The Rat Brain in Steriotaxic Coordinates","author":"Paxinos","year":"1986"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0220","doi-asserted-by":"crossref","first-page":"17649","DOI":"10.1523\/JNEUROSCI.4871-11.2011","article-title":"Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease","volume":"31","author":"Pickrell","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0225","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.neuropharm.2004.11.009","article-title":"KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse","volume":"48","author":"Pierri","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0230","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","article-title":"The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease","volume":"30","author":"Reardon","year":"2000","journal-title":"Aust. N. Z. J. Med."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0235","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.nbd.2008.03.003","article-title":"Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS","volume":"31","author":"Rodriguez-Pallares","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0245","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.expneurol.2010.05.015","article-title":"Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease","volume":"224","author":"Rodriguez-Perez","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0240","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/brain\/awr320","article-title":"Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system","volume":"135","author":"Rodriguez-Perez","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0250","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10571-011-9754-6","article-title":"Angiotensin II AT(1) receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders","volume":"32","author":"Saavedra","year":"2012","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0255","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10571-006-9009-0","article-title":"Mechanisms of the Anti-ischemic effect of angiotensin II AT(1) receptor antagonists in the brain","volume":"26","author":"Saavedra","year":"2006","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0260","first-page":"945","article-title":"In vivo Angiotensin II AT1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland","volume":"23","author":"Sanchez-Lemus","year":"2009","journal-title":"Brain Behav. Evol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0265","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(11)61305-6","article-title":"Mitochondrial diseases","volume":"379","author":"Schapira","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2013.10.014_bb0270","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1460-9568.2009.06657.x","article-title":"PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease","volume":"29","author":"Schintu","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0275","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/01.hjh.0000220417.01397.6a","article-title":"Angiotensin II type 1 receptors in cerebral ischaemia-reperfusion: initiation of inflammation","volume":"24","author":"Schulz","year":"2006","journal-title":"J. Hypertens. Suppl."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0280","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/nprot.2006.305","article-title":"A high-throughput fluorimetric assay for angiotensin I-converting enzyme","volume":"1","author":"Schwager","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0285","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.expneurol.2012.01.022","article-title":"Caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease","volume":"234","author":"Sonsalla","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0290","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/j.1471-4159.1986.tb01768.x","article-title":"Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium","volume":"46","author":"Vyas","year":"1986","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0295","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1476-5381.2010.00840.x","article-title":"Angiotensin receptor type 1 antagonists protect against neuronal injury induced by oxygen-glucose depletion","volume":"161","author":"Wu","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0300","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.expneurol.2006.02.002","article-title":"Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+)","volume":"200","author":"Yazdani","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0305","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ana.21313","article-title":"Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms","volume":"63","author":"Yu","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0310","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1006\/exnr.1999.7283","article-title":"NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum","volume":"161","author":"Zeevalk","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.10.014_bb0315","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.expneurol.2006.09.004","article-title":"Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease","volume":"203","author":"Zeevalk","year":"2007","journal-title":"Exp. Neurol."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488613003178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488613003178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T18:58:51Z","timestamp":1746039531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488613003178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":63,"alternative-id":["S0014488613003178"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2013.10.014","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2013.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}